NPPA fixes retail price of 33 formulations, details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 33 drugs, including those used to treat high blood pressure, type 2 diabetes, etc. under the Drugs (Prices Control) Order, 2013.
The list includes Skymap Pharmaceutical/ Glensmith Lab's Vildagliptin plus Metformin Hydrochloride Tablet, Ravenbhel Healthcare/ Unison Pharmaceutical's Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet.
The list further includes Mascot Health Series/ Eris Lifesciences Atorvastatin and Ezetimibe Tablets, Ravenbhel Healthcare/ Zuventus Healthcare's Cholecalciferol (Vitamin D3) Oral Solution 60000IU, Pure and Cure Healthcare and La Renon Healthcare's Telmisartan and Metoprolol Succinate (ER) Tablet, Scott-Edil Advance Research Laboratories and Education/J.B. Chemicals and Pharmaceutical's Ceftriaxone and Sulbactam for Injection.
The notice declared that in the exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 10.04 |
2 | Amoxycillin + Potassium Clavulanate Oral Suspension | Each combi pack contains: (A) Amoxycillin and Potassium Clavulanate Oral Suspension IP Each 5ml of Reconstituted suspension contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57mg (B) Sterile water for Reconsitution-30 ml | 1 ml | M/s Malik Life Sciences Pvt. Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. | 4.16 |
3 | Vildagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Vildagliptin IP 50mg Metformin Hydrochloride IP 1000mg | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 8.32 |
4 | Vildagliptin + Metformin Hydrochloride Tablet | Each film coated tablet contains: Vildagliptin IP 50mg Metformin Hydrochloride IP | 1 Tablet | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs | 7.89 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
500mg | Pvt. Ltd. | ||||
5 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 9.62 |
6 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 11.31 |
7 | Metoprolol Succinate Extended Release, Cilnidipine & Telmisartan Tablet | Each film coated bilayered tablet contains: Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate 50mg (As Extended release) Telmisartan IP 40mg, Cilnidipine IP 10mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Unison Pharmaceuticals Pvt. Ltd. | 12.46 |
8 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 20mg Ezetimibe IP 10mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 23.85 |
9 | Atorvastatin & Ezetimibe Tablets | Each film coated tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40mg Ezetimibe IP 10mg | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Eris Lifesciences Limited | 32.61 |
10 | Cholecalciferol (Vitamin D3) Oral Solution 60000IU | Each 5ml Syrup contains: Cholecalciferol 60000 IU | 1 ml | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zuventus Healthcare Limited | 12.27 |
11 | Telmisartan and Metoprolol Succinate (ER) Tablet | Each film coated bilayered tablet contains: Telmisartan IP 40mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (as extended- release form) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | 11.96 |
12 | Ceftriaxone & Sulbactam for Injection | Each vial contains: Sterile Ceftriaxone Sodium IP eq. to Ceftriaxone 1000mg Sterile Sulbactam Sodium IP eq. to Sulbactam 500mg | 1 vial | M/s Scott-Edil Advance Research Laboratories and Eduction Ltd. / M/s J.B. Chemicals & Pharmaceuticals Ltd. | 142.48 |
13 | Bisoprolol Fumarate & Amlodipine tablet | Each film coated tablet contains: Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 6.19 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Amlodipine Besylate IP Eq. to Amlodipine 5mg | |||||
14 | Bisoprolol Fumarate & Amlodipine tablet | Each film coated tablet contains: Bisoprolol Fumarate IP 5mg Amlodipine Besylate IP Eq. to Amlodipine 5mg | 1 Tablet | M/s Unison Pharmaceuticals Pvt. Ltd. | 8.34 |
15 | Amoxycillin & Potassium Clavulanate Oral Suspension IP | Each 5ml (after reconstitution) contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate diluted IP eq. to Clavulanic Acid 57mg | 1 ml | M/s Uni Medico Labs / M/s Torrent Pharmaceuticals Ltd. | 4.20 |
16 | Diclofenac Diethylamine, Methyl Salicylate, Menthol & Virgin Linseed Oil Topical Spray | Composition: Diclofenac Diethylamine IP 1.16%w/w eq. to Diclofenac Sodium IP 1% w/w Virgin Linseed Oil BP 3% w/w Methyl Salicylate IP 10% w/w Menthol IP 5%w/w | 1 Gram | M/s Pontika Aerotech Limited / M/s Blue Cross Laboratories Pvt. Ltd. | 2.83 |
17 | Rabeprazole Sodium and Domperidone SR Capsules | Each hard gelatin capsule contains: Rabeprazole Sodium IP 20mg (As enteric coated pellets) Domperidone IP 30mg (as Sustained release pellets) | 1 Capsule | M/s Aagya Biotech Pvt. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. | 11.52 |
18 | Metronidazole, Lignocaine Hydrochloride and Chlorhexidine Gluconate Gel | Contains: Metronidazole Benzoate IP Metronidazole 1 % w/w Lignocaine Hydrochloride IP 2% w/w Chlorhexidine Gluconate Solution Chlorhexidine Gluconate 1% w/w | 1 Gram | M/s J.B. Chemicals & Pharmaceuticals Ltd. | 4.22 |
19 | Rosuvastatin + Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) | 1 Capsule | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 19.21 |
20 | Rosuvastatin + Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As | 1 Capsule | M/s Skymap Pharmaceuticals Pvt. Ltd. | 19.21 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Pellets) | |||||
21 | Rosuvastatin + Clopidogrel Capsules | Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets) | 1 Capsule | M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd. | 19.21 |
22 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zydus Healthcare Ltd. | 11.36 |
23 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Zydus Healthcare Ltd. | 9.69 |
24 | Hydroxychloroq uine Sulphate tablet | Each film coated tabley contains: Hydroxychloroquine Sulphate IP 300mg | 1 Tablet | M/s Innova Captab Ltd. / M/s Brinton Pharmaceuticals Limited | 13.54 |
25 | Ibuprofen Injection | Each ml contains: Ibuprofen IP 100mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 26.78 |
26 | Paracetamol, Phenylephrine Hydrochloride, Chlorphenirami ne maleate, Ammonium Chloride, Sodium Citrate & Menthol Suspenssion | Each 5ml contains: Paracetamol IP 250mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine maleate IP 2mg Ammonium Chloride IP 120mg Sodium Citrate IP 60mg Menthol IP 1mg | 1 ml | M/s Windlas Biotech Limited / M/s Intas Pharmaceuticals Ltd. | 0.82 |
27 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 13.10 |
28 | Sitagliptin Phosphate, Metformin Hydrochloride and Glimepiride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg | 1 Tablet | M/s Sun Pharma Laboratories Limited | 14.60 |
29 | Linagliptin + | Each film coated bilayer | 1 Tablet | M/s Exemed | 14.37 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Metformin Hydrochloride (ER) Tablet | tablet contains: Linagliptin 5mg Metformin Hydrochloride (as Extended release) IP 1000mg | Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | |||
30 | Budesonide, Glycopyrronium and Formoterol Fumarate Dihydrate Inhaler | Each actuation delivers: Budesonide IP 200mcg Glycopyrronium (as Glycopyrrolate IP) 12.5mcg Formoterol Fumarate Dihydrate suspended in propellant IP 6mcg | Per pack of 120 MDI | M/s Cipla Limited | 855.00 |
31 | Insulin Glargine 100IU /ml and Lixisenatide 50mcg/ml | Each Prefilled pen containing: Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 50mcg/ml | 1ml | M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited | 587.30 |
32 | Insulin Glargine 100IU /ml and Lixisenatide 33mcg/m | Each Prefilled pen containing: Fixed Ratio combination of Insulin Glargine 100IU /ml Lixisenatide 33mcg/ml | 1ml | M/s Sanofi Healthcare India Pvt. Ltd. / M/s Sanofi India Limited | 587.30 |
33 | Combikit of Atazanavir + Ritonavir & Emtricitabine + Tenofovir Alafenamide Tablet | Each Combi kit contains: Part A: Each film coated tablet contains: Atazanavir Sulphate IP eq. to Atazanavir 300mg Ritonavir IP 100mg Part B: Each film coated tablet contains: Emtricitabine IP 200mg Tenofovir Alafenamide Fumarate eq. to Tenofovir Alafenamide 10mg | 1 Combi kit | M/s Emcure Pharmaceuticals Limited | 112.60 |
The Notification further added:
(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in (a) column (6) of the above-said table.
(c)The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to the State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above-mentioned retail price is applicable only to the individual manufacturer /marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g))Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer and marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
To view the official notice, click the below link:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.